Page 129 - EJMO-9-3
P. 129
Eurasian Journal of
Medicine and Oncology Zercepac + pyrotinib versus pertuzumab in HER2+ BC
®
positive metastatic breast cancer (PHOEBE): A multicentre, for patients with human epidermal growth factor receptor
open-label, randomised, controlled, phase 3 trial. Lancet 2-positive breast cancer and brain metastases (PERMEATE):
Oncol. 2021;22(3):351-360. A multicentre, single-arm, two-cohort, phase 2 trial. Lancet
doi: 10.1016/S1470-2045(20)30702-6 Oncol. 2022;23(3):353-361.
21. Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine doi: 10.1016/S1470-2045(21)00716-6
Volume 9 Issue 3 (2025) 121 doi: 10.36922/EJMO025100044
